Q-omics provides the consensus-scored SERINC5 profile across patient tissues and cancer cell-line models. SERINC5 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, SERINC5 is differentially expressed in 11, with the highest sampling consensus in BRCA. Additionally, SERINC5 RNA expression shows 20,018 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight UVM, BRCA, and THYM as cancer lineages where SERINC5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SERINC5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SERINC5 survival associations across molecular data types. SERINC5 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (1) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SERINC5 RNA expression–survival associations across cancer types. High SERINC5 expression shows unfavorable associations in UVM and KIRP, but favorable associations in HNSC, KIRC, LAML and LGG. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify UVM as the clearest survival context for SERINC5 RNA expression.
This table summarizes SERINC5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 2. The strongest signals are observed in BRCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for SERINC5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SERINC5 shows lower tumor expression in KIRC and higher tumor expression in BRCA, STAD, UCEC, BLCA and THCA. The BRCA box plot shows higher SERINC5 RNA expression in tumor versus normal tissue (log2 FC = +0.399, t-test p < 0.001).
This table shows molecular features associated with SERINC5 in patient tissues and cancer cell lines. In patient samples, SERINC5 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, SERINC5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BLOOD_Leukemia.
